Description
Cefuroxime is a well-characterized and effective antibacterial agent, which has broad-spectrum bactericidal activity against a wide range of common pathogens, including Beta-lactamase producing strains. Cefuroxime has good stability to bacterial Beta-lactamase and consequently, is active against many Ampicillin-resistant and Amoxicillin-resistant strains. Clavulanic Acid has a similar structure to the beta-lactam antibiotics but binds irreversibly to the beta-lactamase enzymes. The presence of Clavulanic Acid in Famiclav formulations protects Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins.
Composition
Famiclav 250 Tablet : Each film-coated tablet contains Cefuroxime 250 mg as Cefuroxime Axetil USP and Clavulanic acid 62.50 mg as diluted Potassium Clavulanate BP.
Famiclav 500 Tablet : Each film-coated tablet contains Cefuroxime 500 mg as Cefuroxime Axetil USP and Clavulanic acid 125 mg as diluted Potassium Clavulanate BP.
Famiclav Powder for Suspension: After reconstitution, each 5 ml suspension contains Cefuroxime 125 mg as Cefuroxime Axetil USP and Clavulanic acid 31.25 mg as diluted Potassium Clavulanate BP.
Indications
• Upper respiratory tract infections: Ear, nose and throat infections such as otitis media, sinusitis, tonsillitis and pharyngitis.
• Lower respiratory tract infection : Acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia.
• Skin and soft tissue infections : Furunculosis, pyoderma and impetigo.
• Genito-urinary tract infections: Pyelonephritis, urethritis and cystitis.
• Gonorrhoea: Acute uncomplicated gonococcal urethritis and cervicitis.
• Early Lyme Disease and subsequent prevention of late Lyme Disease
OR AS DIRECTED BY THE PHYSICIAN.
